Last reviewed · How we verify

paraurethral injection of MDCs

Royan Institute · Phase 1 active Biologic Quality 0/100

paraurethral injection of MDCs is a Biologic drug developed by Royan Institute. It is currently in Phase 1 development. Also known as: MDCs transplantion by paraurethral injection..

At a glance

Generic nameparaurethral injection of MDCs
Also known asMDCs transplantion by paraurethral injection.
SponsorRoyan Institute
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about paraurethral injection of MDCs

What is paraurethral injection of MDCs?

paraurethral injection of MDCs is a Biologic drug developed by Royan Institute.

Who makes paraurethral injection of MDCs?

paraurethral injection of MDCs is developed by Royan Institute (see full Royan Institute pipeline at /company/royan-institute).

Is paraurethral injection of MDCs also known as anything else?

paraurethral injection of MDCs is also known as MDCs transplantion by paraurethral injection..

What development phase is paraurethral injection of MDCs in?

paraurethral injection of MDCs is in Phase 1.

Related